PROCEPT BioRobotics (PRCT) Competitors $81.17 +0.39 (+0.48%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRCT vs. SOLV, SNN, PEN, GKOS, BLCO, INSP, AXNX, NVCR, NVST, and NARIShould you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Axonics (AXNX), NovoCure (NVCR), Envista (NVST), and Inari Medical (NARI). These companies are all part of the "medical equipment" industry. PROCEPT BioRobotics vs. Solventum Smith & Nephew Penumbra Glaukos Bausch + Lomb Inspire Medical Systems Axonics NovoCure Envista Inari Medical Solventum (NYSE:SOLV) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Does the MarketBeat Community favor SOLV or PRCT? PROCEPT BioRobotics received 37 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 67.86% of users gave PROCEPT BioRobotics an outperform vote while only 5.56% of users gave Solventum an outperform vote. CompanyUnderperformOutperformSolventumOutperform Votes15.56%Underperform Votes1794.44% PROCEPT BioRoboticsOutperform Votes3867.86% Underperform Votes1832.14% Do analysts rate SOLV or PRCT? Solventum presently has a consensus price target of $68.29, indicating a potential upside of 2.18%. PROCEPT BioRobotics has a consensus price target of $97.86, indicating a potential upside of 20.56%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00PROCEPT BioRobotics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has preferable valuation and earnings, SOLV or PRCT? Solventum has higher revenue and earnings than PROCEPT BioRobotics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolventum$8.26B1.40N/AN/AN/APROCEPT BioRobotics$199.84M21.20-$105.90M-$1.95-41.63 Is SOLV or PRCT more profitable? Solventum has a net margin of 0.00% compared to PROCEPT BioRobotics' net margin of -50.07%. Solventum's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets SolventumN/A N/A N/A PROCEPT BioRobotics -50.07%-38.57%-26.06% Does the media favor SOLV or PRCT? In the previous week, Solventum had 10 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 14 mentions for Solventum and 4 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 1.35 beat Solventum's score of 1.24 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in SOLV or PRCT? 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryPROCEPT BioRobotics beats Solventum on 9 of the 14 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get PROCEPT BioRobotics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRCT vs. The Competition Export to ExcelMetricPROCEPT BioRoboticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.24B$4.33B$5.12B$9.07BDividend YieldN/A41.46%4.91%4.22%P/E Ratio-41.6325.3791.3417.19Price / Sales21.2045.671,116.63116.80Price / CashN/A43.4642.5837.86Price / Book14.607.364.794.78Net Income-$105.90M$13.64M$120.07M$225.60M7 Day Performance-9.04%-2.81%-1.90%-1.24%1 Month Performance-14.06%0.55%11.43%3.06%1 Year Performance90.76%41.80%30.59%16.50% PROCEPT BioRobotics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRCTPROCEPT BioRobotics2.7844 of 5 stars$81.17+0.5%$97.86+20.6%+102.9%$4.24B$199.84M-41.63626Positive NewsSOLVSolventum1.3032 of 5 stars$69.80+0.3%$68.29-2.2%N/A$12.06BN/A0.0022,000Positive NewsSNNSmith & Nephew3.7078 of 5 stars$25.49-0.2%N/A-7.3%$11.14B$5.55B13.0318,452News CoveragePENPenumbra4.2288 of 5 stars$248.21+1.1%$252.42+1.7%-1.8%$9.53B$1.16B285.524,200Analyst ForecastGKOSGlaukos4.115 of 5 stars$143.66+3.4%$143.17-0.3%+89.5%$7.92B$360.35M-46.00780Analyst ForecastShort Interest ↓BLCOBausch + Lomb2.9392 of 5 stars$18.56-0.2%$20.58+10.9%+16.9%$6.54B$4.68B-17.7113,300INSPInspire Medical Systems4.6549 of 5 stars$188.13+0.2%$233.58+24.2%+1.7%$5.64B$755.59M176.781,011Positive NewsAXNXAxonics1.4257 of 5 stars$70.98+0.8%$71.00+0.0%+20.9%$3.63B$366.38M-591.45610High Trading VolumeNVCRNovoCure2.7417 of 5 stars$32.75-2.0%$32.67-0.3%+138.4%$3.54B$577.74M-23.861,453NVSTEnvista3.9067 of 5 stars$19.58+0.6%$20.65+5.5%-21.1%$3.37B$2.50B-2.5112,800Positive NewsNARIInari Medical3.3152 of 5 stars$55.12-0.8%$58.89+6.8%-11.9%$3.23B$574.50M-41.181,300Analyst ForecastInsider Trade Related Companies and Tools Related Companies SOLV Competitors SNN Competitors PEN Competitors GKOS Competitors BLCO Competitors INSP Competitors AXNX Competitors NVCR Competitors NVST Competitors NARI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRCT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRCT Stock Alerts